Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes

New Orleans, US, 12 June 2016 - Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented today at the American Diabetes Association 76^th Scientific Sessions.^1,2 In the SUSTAIN 2 trial, 0.5 mg and 1.0 mg semaglutide administered once-weekly significantly improved glycaemic control compared to sitagliptin (100 mg), a dipeptidyl peptidase-4 (DPP-4) inhibitor, in adults with type 2 diabetes (ref 1). In the SUSTAIN 3 trial, 1.0 mg semaglutide administered once-weekly significantly improved glycaemic control compared to 2.0 mg exenatide extended-release (ER), a GLP-1 receptor agonist, in adults with type 2 diabetes (ref 2).

Further information

Attachment